Trial Outcomes & Findings for Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) (NCT NCT00542178)

Last Updated: 2018-07-24

Results Overview

Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

3472 participants

Primary outcome timeframe

Measured at Year 4

Results posted on

2018-07-24

Participant Flow

Recruitment for the ACCORD Eye study was restricted to participants recruited as part of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. The ACCORD Eye study began in October 2003, with 3472 participants enrolled by February 2006.

All participants were enrolled in either the intensive or standard glycemia control arms. In addition to inclusion in the glycemia control part of the trial, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo).

Participant milestones

Participant milestones
Measure	Intensive Glycemia Control & Intensive Blood Pressure Control Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg	Standard Glycemia Control & Intensive Blood Pressure Control Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg	Intensive Glycemia Control & Standard Blood Pressure Control Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg	Standard Glycemia Control & Standard Blood Pressure Control Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg	Intensive Glycemia Control & Fibrate Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d	Standard Glycemia Control & Fibrate Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d	Intensive Glycemia Control & Fibrate Placebo Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d	Standard Glycemia Control & Fibrate Placebo Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d
Overall Study STARTED	390	412	382	370	464	495	493	466
Overall Study COMPLETED	315	332	308	308	400	406	406	381
Overall Study NOT COMPLETED	75	80	74	62	64	89	87	85

Reasons for withdrawal

Reasons for withdrawal
Measure	Intensive Glycemia Control & Intensive Blood Pressure Control Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg	Standard Glycemia Control & Intensive Blood Pressure Control Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Intensive Blood Pressure Control: A strategy of BP treatment for SBP less than 120 mm Hg	Intensive Glycemia Control & Standard Blood Pressure Control Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg	Standard Glycemia Control & Standard Blood Pressure Control Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Standard Blood Pressure Control: A strategy of BP treatment for SBP less than 140 mm Hg	Intensive Glycemia Control & Fibrate Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d	Standard Glycemia Control & Fibrate Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Fibrate: Blinded fenofibrate + simvastatin 20-40 mg/d	Intensive Glycemia Control & Fibrate Placebo Intensive Glycemia Control: A strategy of intensive glycemia treatment to HbA1c less than 6% Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d	Standard Glycemia Control & Fibrate Placebo Standard Glycemia Control: A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9% Fibrate Placebo: Blinded placebo + simvastatin 20-40 mg/d
Overall Study did not complete year 4 follow-up	75	80	74	62	64	89	87	85

Baseline Characteristics

All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Intensive Glycemia Control n=1429 Participants A strategy of intensive glycemia treatment to HbA1c less than 6%	Standard Glycemia Control n=1427 Participants A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%	Intensive BP Control n=647 Participants A strategy of BP treatment for SBP less than 120 mm Hg	Standard BP Control n=616 Participants A strategy of BP treatment for SBP less than 140 mm Hg	Fibrate n=806 Participants Blinded fenofibrate + simvastatin 20-40 mg/d	Fibrate Placebo n=787 Participants Blinded placebo + simvastatin 20-40 mg/d	Total n=5712 Participants Total of all reporting groups
Age, Continuous	61.6 years STANDARD_DEVIATION 6.4 • n=1429 Participants	61.5 years STANDARD_DEVIATION 6.3 • n=1427 Participants	61.3 years STANDARD_DEVIATION 6.1 • n=647 Participants	61.5 years STANDARD_DEVIATION 6.6 • n=616 Participants	61.9 years STANDARD_DEVIATION 6.2 • n=806 Participants	61.5 years STANDARD_DEVIATION 6.5 • n=787 Participants	61.6 years STANDARD_DEVIATION 6.3 • n=5712 Participants
Sex: Female, Male Glycemic Control Study · Female	538 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	552 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1090 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Sex: Female, Male Glycemic Control Study · Male	891 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	875 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1766 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Sex: Female, Male Blood Pressure and Lipid Studies · Female	—	—	310 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	279 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	247 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	254 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1090 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Sex: Female, Male Blood Pressure and Lipid Studies · Male	—	—	337 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	337 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	559 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	533 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1766 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Duration of diabetes Glycemic Control Study	9.8 year STANDARD_DEVIATION 7.1 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	10.1 year STANDARD_DEVIATION 7.2 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	10.0 year STANDARD_DEVIATION 7.1 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Duration of diabetes Blood Pressure and Lipid Studies	—	—	10.1 year STANDARD_DEVIATION 7.0 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	10.3 year STANDARD_DEVIATION 7.5 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	9.7 year STANDARD_DEVIATION 6.8 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	9.8 year STANDARD_DEVIATION 7.2 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	10.0 year STANDARD_DEVIATION 7.1 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Previous cardiovascular event Glycemic Control Study · Previous cardiovascular event	452 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	443 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	895 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Previous cardiovascular event Glycemic Control Study · No previous cardiovascular event	977 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	984 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1961 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Previous cardiovascular event Blood Pressure and Lipid Studies · Previous cardiovascular event	—	—	180 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	197 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	263 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	255 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	895 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Previous cardiovascular event Blood Pressure and Lipid Studies · No previous cardiovascular event	—	—	467 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	419 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	543 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	532 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1961 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Race Glycemic Control Study · Nonwhite race	427 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	433 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	860 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Race Glycemic Control Study · White race	1002 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	994 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1996 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Race Blood Pressure and Lipid Studies · Nonwhite race	—	—	203 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	201 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	222 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	234 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	860 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Race Blood Pressure and Lipid Studies · White race	—	—	444 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	415 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	584 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	553 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1996 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Glycated hemoglobin Glycemic Control Study	8.2 percent STANDARD_DEVIATION 1.0 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	8.3 percent STANDARD_DEVIATION 1.0 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	8.2 percent STANDARD_DEVIATION 1.0 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Glycated hemoglobin Blood Pressure and Lipid Studies	—	—	8.4 percent STANDARD_DEVIATION 1.1 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	8.2 percent STANDARD_DEVIATION 1.0 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	8.2 percent STANDARD_DEVIATION 1.0 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	8.2 percent STANDARD_DEVIATION 1.0 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	8.2 percent STANDARD_DEVIATION 1.0 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Cholesterol (HDL) Glycemic Control Study	42.0 mg/dl STANDARD_DEVIATION 11.4 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	41.9 mg/dl STANDARD_DEVIATION 11.1 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	41.9 mg/dl STANDARD_DEVIATION 11.3 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Cholesterol (HDL) Blood Pressure and Lipid Studies	—	—	46.3 mg/dl STANDARD_DEVIATION 12.8 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	46.31 mg/dl STANDARD_DEVIATION 13.8 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	38.6 mg/dl STANDARD_DEVIATION 7.8 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	38.5 mg/dl STANDARD_DEVIATION 7.9 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	41.9 mg/dl STANDARD_DEVIATION 11.3 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Cholesterol (LDL) Glycemic Control Study	100.8 mg/dl STANDARD_DEVIATION 33.4 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	100.7 mg/dl STANDARD_DEVIATION 32.1 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	100.7 mg/dl STANDARD_DEVIATION 32.7 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Cholesterol (LDL) Blood Pressure and Lipid Studies	—	—	107.4 mg/dl STANDARD_DEVIATION 37.0 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	104.1 mg/dl STANDARD_DEVIATION 33.5 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	96.5 mg/dl STANDARD_DEVIATION 29.7 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	97.0 mg/dl STANDARD_DEVIATION 30.1 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	100.7 mg/dl STANDARD_DEVIATION 32.7 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Triglycerides Glycemic Control Study	196.1 mg/dl STANDARD_DEVIATION 157.8 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	194 mg/dl STANDARD_DEVIATION 167.3 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	195.1 mg/dl STANDARD_DEVIATION 162.6 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Triglycerides Blood Pressure and Lipid Studies	—	—	200.7 mg/dl STANDARD_DEVIATION 175.5 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	204.7 mg/dl STANDARD_DEVIATION 240.3 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	190.1 mg/dl STANDARD_DEVIATION 111.3 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	187.9 mg/dl STANDARD_DEVIATION 112.4 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	195.1 mg/dl STANDARD_DEVIATION 162.6 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Systolic Blood pressure Glycemic Control Study	134.3 mm Hg STANDARD_DEVIATION 16.6 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	134.7 mm Hg STANDARD_DEVIATION 17.4 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	134.5 mm Hg STANDARD_DEVIATION 17.0 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Systolic Blood pressure Blood Pressure and Lipid Studies	—	—	138.0 mm Hg STANDARD_DEVIATION 16.7 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	139.0 mm Hg STANDARD_DEVIATION 14.7 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	131.5 mm Hg STANDARD_DEVIATION 17.0 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	131.1 mm Hg STANDARD_DEVIATION 17.5 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	134.5 mm Hg STANDARD_DEVIATION 17.0 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Diastolic Blood Pressure Glycemic Control Study	74.9 mm Hg STANDARD_DEVIATION 10.3 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	75.0 mm Hg STANDARD_DEVIATION 10.6 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	74.9 mm Hg STANDARD_DEVIATION 10.5 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Diastolic Blood Pressure Blood Pressure and Lipid Studies	—	—	76.3 mm Hg STANDARD_DEVIATION 10.5 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	76.8 mm Hg STANDARD_DEVIATION 9.9 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	73.7 mm Hg STANDARD_DEVIATION 10.5 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	73.6 mm Hg STANDARD_DEVIATION 10.5 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	74.9 mm Hg STANDARD_DEVIATION 10.5 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Urinary albumin:creatinine ratio Glycemic Control Study	69.5 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 2228.9 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	74.0 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 275.3 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	71.8 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 253.1 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Urinary albumin:creatinine ratio Blood Pressure and Lipid Studies	—	—	62.5 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 197.6 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	79.2 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 269.9 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	62.3 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 180.2 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	83.2 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 331.5 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	71.8 albumin (mg/dL): creatinin (g/dL) STANDARD_DEVIATION 253.1 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
BMI Glycemic Control Study	32.4 kg/m^2 STANDARD_DEVIATION 5.5 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	32.5 kg/m^2 STANDARD_DEVIATION 5.4 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	32.4 kg/m^2 STANDARD_DEVIATION 5.5 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
BMI Blood Pressure and Lipid Studies	—	—	32.7 kg/m^2 STANDARD_DEVIATION 5.7 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	32.2 kg/m^2 STANDARD_DEVIATION 5.3 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	32.3 kg/m^2 STANDARD_DEVIATION 5.5 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	32.6 kg/m^2 STANDARD_DEVIATION 5.4 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	32.4 kg/m^2 STANDARD_DEVIATION 5.5 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Visual acuity Glycemic Control Study	75.9 letters STANDARD_DEVIATION 10.4 • n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	75.9 letters STANDARD_DEVIATION 10.0 • n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	75.9 letters STANDARD_DEVIATION 10.2 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Visual acuity Blood Pressure and Lipid Studies	—	—	75.6 letters STANDARD_DEVIATION 10.3 • n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	75.5 letters STANDARD_DEVIATION 10.2 • n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	76.2 letters STANDARD_DEVIATION 9.7 • n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	76.2 letters STANDARD_DEVIATION 10.7 • n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	75.9 letters STANDARD_DEVIATION 10.2 • n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Glycemic Control Study · Never smoked	581 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	607 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1188 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Glycemic Control Study · Former Smoker	657 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	623 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1280 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Glycemic Control Study · Current Smoker	191 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	196 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	387 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Glycemic Control Study · Missing	0 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Blood Pressure and Lipid Studies · Never smoked	—	—	279 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	263 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	313 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	333 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1188 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Blood Pressure and Lipid Studies · Former Smoker	—	—	279 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	276 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	373 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	352 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1280 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Blood Pressure and Lipid Studies · Current Smoker	—	—	89 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	77 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	119 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	102 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	387 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Smoking status Blood Pressure and Lipid Studies · Missing	—	—	0 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	0 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	0 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Glycemic Control Study · None	729 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	721 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	1450 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Glycemic Control Study · Mild	241 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	277 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	518 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Glycemic Control Study · Moderate Nonproliferative Diabetic Retinopathy	443 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	404 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	847 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Glycemic Control Study · Severe Nonproliferative Diabetic Retinopathy	5 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	5 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	10 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Glycemic Control Study · Proliferative diabetic retinopathy	10 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	19 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	29 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Glycemic Control Study · Missing	1 Participants n=1429 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1 Participants n=1427 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	—	—	—	—	2 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Blood Pressure and Lipid Studies · None	—	—	328 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	295 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	429 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	398 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1450 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Blood Pressure and Lipid Studies · Mild	—	—	105 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	117 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	141 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	155 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	518 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Blood Pressure and Lipid Studies · Moderate Nonproliferative Diabetic Retinopathy	—	—	195 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	198 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	230 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	224 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	847 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Blood Pressure and Lipid Studies · Severe Nonproliferative Diabetic Retinopathy	—	—	3 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	1 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	2 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	4 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	10 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Blood Pressure and Lipid Studies · Proliferative diabetic retinopathy	—	—	14 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	5 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	4 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	6 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	29 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.
Severity of Diabetic Retinopathy Blood Pressure and Lipid Studies · Missing	—	—	2 Participants n=647 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	0 Participants n=616 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	0 Participants n=806 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	0 Participants n=787 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.	2 Participants n=2856 Participants • All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.

PRIMARY outcome

Timeframe: Measured at Year 4

Population: The ACCORD Eye study recruited 3472 eligible participants. Of these, 2856 participants had both baseline and year 4 follow-up data available for analyses.

Outcome measures

Outcome measures
Measure	Intensive Glycemia Control n=1429 Participants Strategy of intensive glycemia treatment to HbA1c less than 6%	Standard Glycemia Control n=1427 Participants Strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%	Intensive Blood Pressure Control n=647 Participants A strategy of BP treatment for SBP less than 120 mmHg	Standard Blood Pressure Control n=616 Participants Strategy of BP treatment for SBP less than 140 mmHg	Fenofibrate + Simvastatin Therapy n=806 Participants Blinded fenofibrate + simvastatin 20-40 mg/d	Placebo + Simvastatin Therapy n=787 Participants Blinded placebo + simvastatin 20-40 mg/d
Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy	104 participants	149 participants	67 participants	54 participants	52 participants	80 participants

SECONDARY outcome

Timeframe: Measured at Year 4

Population: Subset of Participants from the entire ACCORD cohort (NCT00000620) who provided information about loss in visual acuity.

Outcome measures

Outcome measures
Measure	Intensive Glycemia Control n=3466 Participants Strategy of intensive glycemia treatment to HbA1c less than 6%	Standard Glycemia Control n=3511 Participants Strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%	Intensive Blood Pressure Control n=1629 Participants A strategy of BP treatment for SBP less than 120 mmHg	Standard Blood Pressure Control n=1617 Participants Strategy of BP treatment for SBP less than 140 mmHg	Fenofibrate + Simvastatin Therapy n=1883 Participants Blinded fenofibrate + simvastatin 20-40 mg/d	Placebo + Simvastatin Therapy n=1848 Participants Blinded placebo + simvastatin 20-40 mg/d
Loss of Visual Acuity	744 Participants	752 Participants	367 Participants	382 Participants	354 Participants	393 Participants

SECONDARY outcome

Timeframe: Measured at Year 4

Population: Subset of Participants from the entire ACCORD cohort (NCT00000620) who provided information regarding whether or not they had a cataract extraction.

Outcome measures

Outcome measures
Measure	Intensive Glycemia Control n=4361 Participants Strategy of intensive glycemia treatment to HbA1c less than 6%	Standard Glycemia Control n=4405 Participants Strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%	Intensive Blood Pressure Control n=2053 Participants A strategy of BP treatment for SBP less than 120 mmHg	Standard Blood Pressure Control n=2039 Participants Strategy of BP treatment for SBP less than 140 mmHg	Fenofibrate + Simvastatin Therapy n=2333 Participants Blinded fenofibrate + simvastatin 20-40 mg/d	Placebo + Simvastatin Therapy n=2341 Participants Blinded placebo + simvastatin 20-40 mg/d
Cataract Extraction	547 Participants	623 Participants	266 Participants	300 Participants	305 Participants	299 Participants

SECONDARY outcome

Timeframe: Measured at Year 4